{"gene":"HSPB3","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2000,"finding":"HSPB3 and HSPB2/MKBP form a muscle-specific oligomeric complex (~150 kDa) that is completely independent of oligomers formed by HSP27, alphaB-crystallin, and p20. Expression of both HSPB2 and HSPB3 is induced during myogenic differentiation under control of MyoD. Unlike HSPB2, HSPB3 does not interact with myotonic dystrophy protein kinase, and neither HSPB2 nor HSPB3 associates with actin bundles in myotubes.","method":"Co-immunoprecipitation, gel filtration, tissue distribution analysis, immunofluorescence localization in myotubes, myogenic differentiation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP and multiple orthogonal methods (gel filtration, immunofluorescence, differentiation assays) in a single thorough study","pmids":["10625651"],"is_preprint":false},{"year":2009,"finding":"Recombinant HSPB2 and HSPB3 form well-defined hetero-oligomers (tetramers to 24-mers) with a strict 3:1 HSPB2:HSPB3 subunit ratio. The HSPB2/B3 complex shows poor chaperone-like and thermoprotective activity correlated with low surface hydrophobicity. When HSPB3 is complexed with HSPB2, the resulting oligomer cannot interact with HSP20, HSP27, or alphaB-crystallin, whereas homomeric HSPB2 (not in complex with HSPB3) can associate with HSP20.","method":"Nanoelectrospray ionization mass spectrometry, sedimentation velocity analytical ultracentrifugation, far-UV circular dichroism spectroscopy, ANS hydrophobicity assay, co-immunoprecipitation, in vitro chaperone activity assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution from recombinant proteins, multiple orthogonal biophysical methods, and functional chaperone assays in a single rigorous study","pmids":["19715703"],"is_preprint":false},{"year":2012,"finding":"Recombinant human HspB3 forms polydisperse oligomers with predominantly trimeric species, exhibits beta-sheet secondary structure, and has molecular chaperone-like activity preventing heat-induced aggregation of ADH and citrate synthase but does NOT prevent DTT-induced aggregation of insulin, demonstrating target protein-dependent chaperone activity. Fusion of the alphaB-crystallin C-terminal extension to HspB3 alters its quaternary structure and increases chaperone activity toward insulin, revealing that the short C-terminal extension of HspB3 restricts its substrate range.","method":"Gel filtration, sedimentation velocity analytical ultracentrifugation, circular dichroism, in vitro chaperone aggregation assays (ADH, citrate synthase, insulin), chimeric protein engineering","journal":"Cell biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with recombinant protein, multiple substrates tested, domain-swap mutagenesis, single lab","pmids":["22610661"],"is_preprint":false},{"year":2018,"finding":"Crystal structure of full-length human HspB2/HspB3 hetero-tetramer (3:1 ratio) shows four alpha-crystallin domains assembling into a flattened tetrahedron. Assembly is mediated by IXI/V motifs from terminal regions filling ACD pockets, and parts of the N-terminal region bind in an unfolded conformation into anti-parallel shared ACD dimer grooves, revealing a plasticity in terminal-region interactions.","method":"X-ray crystallography of full-length human HspB2/B3 hetero-tetramer","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — atomic-resolution crystal structure of full-length heteromer with functional domain annotation","pmids":["29969581"],"is_preprint":false},{"year":2005,"finding":"HSP22/HSPB8 interacts with alphaB-crystallin and HSP20 but does NOT interact detectably with HSPB3 by yeast two-hybrid or FRET; HSPB3 is found in high-molecular-weight HPLC fractions of primate cardiac muscle together with alphaB-crystallin and HSP20, consistent with its participation in large complexes.","method":"Yeast two-hybrid assay, FRET microscopy, HPLC fractionation of cardiac muscle extracts","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal methods (yeast two-hybrid and FRET) for interaction testing; fractionation data is correlative; single lab","pmids":["16225851"],"is_preprint":false},{"year":2017,"finding":"In mammalian cells, HSPB3 negatively regulates the interaction of HSPB2 with the co-chaperone BAG3: overexpression of HSPB3 reduces HSPB2-BAG3 association, whereas in human myoblasts expressing endogenous HSPB2, HSPB3, HSPB8, and BAG3, BAG3 interacts selectively with HSPB8 and not with HSPB2 or HSPB3.","method":"Co-immunoprecipitation in mammalian (overexpression) and human myoblast (endogenous) cells","journal":"Cell stress & chaperones","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — Co-IP in two cellular contexts (overexpression and endogenous), single lab, no in vitro reconstitution","pmids":["28181153"],"is_preprint":false},{"year":2021,"finding":"HSPB3 binds to the lamin B receptor (LBR) in the nucleoplasm and maintains LBR in a dynamic state, promoting transcription of myogenic genes including extracellular matrix remodeling genes. Depletion of HSPB3 prevents myoblast differentiation. Overexpression of HSPB3 alone is sufficient to induce differentiation of LHCNM2 and rhabdomyosarcoma cells. The disease-associated mutant R116P-HSPB3 forms nuclear aggregates that immobilize LBR and activates the unfolded protein response, failing to induce differentiation.","method":"Co-immunoprecipitation (HSPB3-LBR), FRAP (LBR dynamics), siRNA knockdown, HSPB3 overexpression in human muscle cell lines, immunofluorescence, gene expression analysis","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, FRAP for dynamics, loss-of-function (siRNA) and gain-of-function (overexpression) with defined differentiation phenotype, disease mutant validation; single lab but multiple orthogonal methods","pmids":["33958580"],"is_preprint":false},{"year":2016,"finding":"HSPB3 protein is expressed in motoneurons in vivo (spinal cord of chicken, mouse, and human). Overexpression of wild-type HSPB3 in an avian limb-bud removal model of motoneuron degeneration promotes motoneuron survival, while mutant HSPB3 does not provide the same survival benefit.","method":"In ovo overexpression in avian motoneuron degeneration model, immunohistochemistry for endogenous localization, motoneuron survival counts","journal":"Experimental neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — defined cellular phenotype (motoneuron survival) with direct localization; single lab, single in vivo assay system","pmids":["27567740"],"is_preprint":false},{"year":2023,"finding":"The disease-associated HSPB3 Y118H mutant induces loss of motor activity and reduces mitochondrial membrane potential in Drosophila neuronal tissues. Mitophagy is downregulated in fly motor neurons expressing HSPB3 Y118H. Overexpression of PINK1 and Parkin (core mitophagy regulators) rescues both motor and mitochondrial defects caused by the mutant, placing HSPB3 function upstream of or within the PINK1-Parkin mitophagy pathway in neurons.","method":"Drosophila transgenic overexpression, motor activity assays, mitochondrial membrane potential measurement, mitophagy reporter assays, genetic epistasis with PINK1/Parkin","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic epistasis in Drosophila model with defined phenotypic readouts; single lab, first animal model for this mutation","pmids":["37804589"],"is_preprint":false},{"year":1998,"finding":"HspB3 cDNA encodes a 150-amino-acid polypeptide; among six known human sHSPs it is the most divergent, with a unique N-terminal domain and essentially no C-terminal extension. Northern blot shows expression primarily in smooth muscle tissue.","method":"cDNA sequence analysis, Northern blot","journal":"Biochimica et biophysica acta","confidence":"Low","confidence_rationale":"Tier 4 / Weak — sequence/expression characterization only, no functional experiment","pmids":["9858786"],"is_preprint":false}],"current_model":"HSPB3 is a muscle- and neuron-enriched small heat shock protein that obligately hetero-oligomerizes with HSPB2 in a strict 3:1 (HSPB2:HSPB3) ratio to form a structurally distinct complex (crystal structure resolved) with low intrinsic chaperone activity and no interaction with HSP27, HSP20, or alphaB-crystallin; in the nucleus HSPB3 binds the lamin B receptor (LBR) and keeps it dynamic to drive MyoD-dependent myogenic transcription and differentiation, while in motor neurons it supports survival and mitochondrial quality control via the PINK1-Parkin mitophagy axis, with disease-linked mutations (R116P, Y118H) causing nuclear aggregation, LBR immobilization, mitochondrial dysfunction, and failure of differentiation."},"narrative":{"mechanistic_narrative":"HSPB3 is a muscle- and neuron-enriched small heat shock protein whose defining biochemical feature is obligate hetero-oligomerization with HSPB2 into a muscle-specific complex induced during MyoD-driven myogenic differentiation [PMID:10625651]. Reconstitution from recombinant proteins establishes that HSPB2 and HSPB3 assemble in a strict 3:1 (HSPB2:HSPB3) ratio into species ranging from tetramers to 24-mers with low surface hydrophobicity and poor chaperone-like activity, and the crystal structure of the full-length hetero-tetramer shows four alpha-crystallin domains forming a flattened tetrahedron held together by IXI/V-motif and N-terminal contacts [PMID:19715703, PMID:29969581]. On its own HSPB3 has target-dependent chaperone activity that is constrained by its unusually short C-terminal extension [PMID:22610661], and incorporation into the HSPB2/B3 complex restricts its interaction repertoire so that it does not associate with HSP20, HSP27, or alphaB-crystallin [PMID:19715703, PMID:16225851]; HSPB3 also negatively regulates HSPB2 binding to the co-chaperone BAG3 [PMID:28181153]. Beyond chaperoning, HSPB3 has a distinct nuclear function: it binds the lamin B receptor (LBR) and keeps it dynamic, and HSPB3 is both required and sufficient to drive myogenic gene transcription and differentiation, with the disease mutant R116P forming nuclear aggregates that immobilize LBR, trigger the unfolded protein response, and block differentiation [PMID:33958580]. In motor neurons HSPB3 supports neuronal survival [PMID:27567740], and a disease-associated Y118H mutant causes mitochondrial dysfunction and impaired mitophagy that is rescued by PINK1/Parkin, placing HSPB3 within the PINK1-Parkin mitophagy axis [PMID:37804589].","teleology":[{"year":2000,"claim":"Established that HSPB3 is not a free-standing sHSP but a partner of HSPB2 in a muscle-specific complex that is induced during differentiation, distinguishing it from the canonical sHSP network.","evidence":"Co-IP, gel filtration, tissue distribution, and myogenic differentiation assays in myotubes","pmids":["10625651"],"confidence":"High","gaps":["Subunit stoichiometry of the complex not yet resolved","Functional consequence of the HSPB2/B3 complex unknown","Did not test chaperone activity directly"]},{"year":2009,"claim":"Defined the precise architecture and biochemical character of the complex, showing a fixed 3:1 stoichiometry and explaining its poor chaperone activity via low surface hydrophobicity and a restricted interaction repertoire.","evidence":"Native mass spectrometry, analytical ultracentrifugation, CD, ANS hydrophobicity, Co-IP, and in vitro chaperone assays on recombinant proteins","pmids":["19715703"],"confidence":"High","gaps":["No physiological substrate identified","Functional role of the complex in cells not addressed","Atomic structure not yet determined"]},{"year":2012,"claim":"Showed that HSPB3 alone has intrinsic, target-selective chaperone activity and that its short C-terminal extension is the structural determinant restricting its substrate range.","evidence":"Gel filtration, AUC, CD, multi-substrate aggregation assays, and C-terminal chimera engineering with recombinant HspB3","pmids":["22610661"],"confidence":"High","gaps":["In vitro substrates may not reflect physiological clients","Behavior of free HSPB3 versus complexed HSPB3 in cells unclear"]},{"year":2018,"claim":"Provided an atomic-resolution explanation of how the 3:1 hetero-tetramer assembles, revealing IXI/V-motif and N-terminal contacts and unexpected plasticity in terminal-region interactions.","evidence":"X-ray crystallography of the full-length human HspB2/B3 hetero-tetramer","pmids":["29969581"],"confidence":"High","gaps":["Structures of larger oligomeric species not resolved","Structural basis of disease mutations not addressed","Does not explain client recognition"]},{"year":2017,"claim":"Placed HSPB3 within the sHSP/co-chaperone regulatory network by showing it modulates HSPB2-BAG3 association, distinguishing its complex from the BAG3-dependent HSPB8 pathway.","evidence":"Co-IP in overexpression and endogenous human myoblast contexts","pmids":["28181153"],"confidence":"Medium","gaps":["Single lab, no in vitro reconstitution","Functional consequence of altered HSPB2-BAG3 binding not measured","Mechanism of negative regulation unknown"]},{"year":2021,"claim":"Uncovered a chaperone-independent nuclear function: HSPB3 binds LBR and keeps it dynamic to drive myogenic transcription, and demonstrated that a disease mutant immobilizes LBR and blocks differentiation.","evidence":"Reciprocal Co-IP, FRAP, siRNA knockdown, overexpression in human muscle cell lines, and disease-mutant validation","pmids":["33958580"],"confidence":"High","gaps":["Mechanism linking LBR dynamics to transcription not defined","Whether the HSPB2/B3 complex or free HSPB3 mediates this is unclear","Single lab"]},{"year":2016,"claim":"Demonstrated a neuronal role by showing HSPB3 is expressed in motoneurons and that wild-type, but not mutant, HSPB3 promotes motoneuron survival.","evidence":"In ovo overexpression in an avian motoneuron degeneration model with survival counts and immunohistochemistry","pmids":["27567740"],"confidence":"Medium","gaps":["Molecular mechanism of survival benefit not defined","Single in vivo assay system","Endogenous loss-of-function not tested"]},{"year":2023,"claim":"Linked the neuronal HSPB3 disease mutant to mitochondrial quality control, showing Y118H impairs mitophagy and is rescued by PINK1/Parkin, placing HSPB3 in the PINK1-Parkin axis.","evidence":"Drosophila transgenic models with motor assays, mitochondrial membrane potential, mitophagy reporters, and PINK1/Parkin genetic epistasis","pmids":["37804589"],"confidence":"Medium","gaps":["Direct molecular target of HSPB3 in the mitophagy pathway unknown","Single lab, first animal model for this mutation","Whether effect is conserved in mammalian motor neurons untested"]},{"year":null,"claim":"How HSPB3's distinct activities — chaperoning within the HSPB2/B3 complex, nuclear LBR regulation of transcription, and support of mitochondrial quality control in neurons — are mechanistically connected, and how disease mutations disrupt each, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified mechanism linking nuclear and mitochondrial functions","Physiological client proteins of the chaperone activity unidentified","Structural basis of pathogenic mutations not determined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0044183","term_label":"protein folding chaperone","supporting_discovery_ids":[1,2]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[6]}],"localization":[{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[6]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,6]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,2]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[8]}],"complexes":["HSPB2/HSPB3 hetero-oligomer"],"partners":["HSPB2","LBR","BAG3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q12988","full_name":"Heat shock protein beta-3","aliases":["Heat shock 17 kDa protein","HSP 17","Heat shock protein family B member 3","Protein 3"],"length_aa":150,"mass_kda":17.0,"function":"Inhibitor of actin polymerization","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q12988/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HSPB3","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/HSPB3","total_profiled":1310},"omim":[{"mim_id":"618467","title":"SMC5-SMC6 COMPLEX LOCALIZATION FACTOR 1; SLF1","url":"https://www.omim.org/entry/618467"},{"mim_id":"613376","title":"NEURONOPATHY, DISTAL HEREDITARY MOTOR, AUTOSOMAL DOMINANT 4; HMND4","url":"https://www.omim.org/entry/613376"},{"mim_id":"604624","title":"HEAT-SHOCK 27-KD PROTEIN 3; HSPB3","url":"https://www.omim.org/entry/604624"},{"mim_id":"182960","title":"NEURONOPATHY, DISTAL HEREDITARY MOTOR, AUTOSOMAL DOMINANT 1; HMND1","url":"https://www.omim.org/entry/182960"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nuclear speckles","reliability":"Supported"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"heart muscle","ntpm":463.9},{"tissue":"skeletal muscle","ntpm":232.7},{"tissue":"tongue","ntpm":204.1}],"url":"https://www.proteinatlas.org/search/HSPB3"},"hgnc":{"alias_symbol":["HSPL27"],"prev_symbol":[]},"alphafold":{"accession":"Q12988","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12988","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q12988-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q12988-F1-predicted_aligned_error_v6.png","plddt_mean":69.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HSPB3","jax_strain_url":"https://www.jax.org/strain/search?query=HSPB3"},"sequence":{"accession":"Q12988","fasta_url":"https://rest.uniprot.org/uniprotkb/Q12988.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q12988/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q12988"}},"corpus_meta":[{"pmid":"10625651","id":"PMC_10625651","title":"Muscle develops a specific form of small heat shock protein complex composed of MKBP/HSPB2 and HSPB3 during myogenic differentiation.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10625651","citation_count":247,"is_preprint":false},{"pmid":"16225851","id":"PMC_16225851","title":"Interactions of HSP22 (HSPB8) with HSP20, alphaB-crystallin, and HSPB3.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16225851","citation_count":75,"is_preprint":false},{"pmid":"9858786","id":"PMC_9858786","title":"HspB3, the most deviating of the six known human small heat shock proteins.","date":"1998","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/9858786","citation_count":50,"is_preprint":false},{"pmid":"19715703","id":"PMC_19715703","title":"The small heat-shock proteins HSPB2 and HSPB3 form well-defined heterooligomers in a unique 3 to 1 subunit ratio.","date":"2009","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19715703","citation_count":45,"is_preprint":false},{"pmid":"29969581","id":"PMC_29969581","title":"Terminal Regions Confer Plasticity to the Tetrameric Assembly of Human HspB2 and HspB3.","date":"2018","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/29969581","citation_count":38,"is_preprint":false},{"pmid":"8972725","id":"PMC_8972725","title":"Isolation and characterization of a human heart cDNA encoding a new member of the small heat shock protein family--HSPL27.","date":"1996","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/8972725","citation_count":23,"is_preprint":false},{"pmid":"22610661","id":"PMC_22610661","title":"Structural aspects and chaperone activity of human HspB3: role of the \"C-terminal extension\".","date":"2012","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/22610661","citation_count":22,"is_preprint":false},{"pmid":"33958580","id":"PMC_33958580","title":"Small heat-shock protein HSPB3 promotes myogenesis by regulating the lamin B receptor.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33958580","citation_count":20,"is_preprint":false},{"pmid":"27567740","id":"PMC_27567740","title":"HSPB3 protein is expressed in motoneurons and induces their survival after lesion-induced degeneration.","date":"2016","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27567740","citation_count":20,"is_preprint":false},{"pmid":"31709619","id":"PMC_31709619","title":"Heat shock protein beta 3 (HSPB3) is an unfavorable molecular biomarker in colorectal adenocarcinoma.","date":"2019","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/31709619","citation_count":20,"is_preprint":false},{"pmid":"28181153","id":"PMC_28181153","title":"An interaction study in mammalian cells demonstrates weak binding of HSPB2 to BAG3, which is regulated by HSPB3 and abrogated by HSPB8.","date":"2017","source":"Cell stress & chaperones","url":"https://pubmed.ncbi.nlm.nih.gov/28181153","citation_count":19,"is_preprint":false},{"pmid":"29341343","id":"PMC_29341343","title":"Small heat shock protein B3 (HSPB3) mutation in an axonal Charcot-Marie-Tooth disease family.","date":"2018","source":"Journal of the peripheral nervous system : JPNS","url":"https://pubmed.ncbi.nlm.nih.gov/29341343","citation_count":13,"is_preprint":false},{"pmid":"21162133","id":"PMC_21162133","title":"Map3k1, Il6st, Gzmk, and Hspb3 gene coexpression network in the mechanism of freezing reaction in mice.","date":"2010","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/21162133","citation_count":7,"is_preprint":false},{"pmid":"35678958","id":"PMC_35678958","title":"Human HspB1, HspB3, HspB5 and HspB8: Shaping these disease factors during vertebrate evolution.","date":"2022","source":"Cell stress & chaperones","url":"https://pubmed.ncbi.nlm.nih.gov/35678958","citation_count":6,"is_preprint":false},{"pmid":"37804589","id":"PMC_37804589","title":"PINK1 and Parkin rescue motor defects and mitochondria dysfunction induced by a patient-derived HSPB3 mutant in Drosophila models.","date":"2023","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/37804589","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9368,"output_tokens":2953,"usd":0.0362,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10222,"output_tokens":3191,"usd":0.065443,"stage2_stop_reason":"end_turn"},"total_usd":0.101643,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"HSPB3 and HSPB2/MKBP form a muscle-specific oligomeric complex (~150 kDa) that is completely independent of oligomers formed by HSP27, alphaB-crystallin, and p20. Expression of both HSPB2 and HSPB3 is induced during myogenic differentiation under control of MyoD. Unlike HSPB2, HSPB3 does not interact with myotonic dystrophy protein kinase, and neither HSPB2 nor HSPB3 associates with actin bundles in myotubes.\",\n      \"method\": \"Co-immunoprecipitation, gel filtration, tissue distribution analysis, immunofluorescence localization in myotubes, myogenic differentiation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP and multiple orthogonal methods (gel filtration, immunofluorescence, differentiation assays) in a single thorough study\",\n      \"pmids\": [\"10625651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Recombinant HSPB2 and HSPB3 form well-defined hetero-oligomers (tetramers to 24-mers) with a strict 3:1 HSPB2:HSPB3 subunit ratio. The HSPB2/B3 complex shows poor chaperone-like and thermoprotective activity correlated with low surface hydrophobicity. When HSPB3 is complexed with HSPB2, the resulting oligomer cannot interact with HSP20, HSP27, or alphaB-crystallin, whereas homomeric HSPB2 (not in complex with HSPB3) can associate with HSP20.\",\n      \"method\": \"Nanoelectrospray ionization mass spectrometry, sedimentation velocity analytical ultracentrifugation, far-UV circular dichroism spectroscopy, ANS hydrophobicity assay, co-immunoprecipitation, in vitro chaperone activity assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution from recombinant proteins, multiple orthogonal biophysical methods, and functional chaperone assays in a single rigorous study\",\n      \"pmids\": [\"19715703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Recombinant human HspB3 forms polydisperse oligomers with predominantly trimeric species, exhibits beta-sheet secondary structure, and has molecular chaperone-like activity preventing heat-induced aggregation of ADH and citrate synthase but does NOT prevent DTT-induced aggregation of insulin, demonstrating target protein-dependent chaperone activity. Fusion of the alphaB-crystallin C-terminal extension to HspB3 alters its quaternary structure and increases chaperone activity toward insulin, revealing that the short C-terminal extension of HspB3 restricts its substrate range.\",\n      \"method\": \"Gel filtration, sedimentation velocity analytical ultracentrifugation, circular dichroism, in vitro chaperone aggregation assays (ADH, citrate synthase, insulin), chimeric protein engineering\",\n      \"journal\": \"Cell biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with recombinant protein, multiple substrates tested, domain-swap mutagenesis, single lab\",\n      \"pmids\": [\"22610661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Crystal structure of full-length human HspB2/HspB3 hetero-tetramer (3:1 ratio) shows four alpha-crystallin domains assembling into a flattened tetrahedron. Assembly is mediated by IXI/V motifs from terminal regions filling ACD pockets, and parts of the N-terminal region bind in an unfolded conformation into anti-parallel shared ACD dimer grooves, revealing a plasticity in terminal-region interactions.\",\n      \"method\": \"X-ray crystallography of full-length human HspB2/B3 hetero-tetramer\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — atomic-resolution crystal structure of full-length heteromer with functional domain annotation\",\n      \"pmids\": [\"29969581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HSP22/HSPB8 interacts with alphaB-crystallin and HSP20 but does NOT interact detectably with HSPB3 by yeast two-hybrid or FRET; HSPB3 is found in high-molecular-weight HPLC fractions of primate cardiac muscle together with alphaB-crystallin and HSP20, consistent with its participation in large complexes.\",\n      \"method\": \"Yeast two-hybrid assay, FRET microscopy, HPLC fractionation of cardiac muscle extracts\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal methods (yeast two-hybrid and FRET) for interaction testing; fractionation data is correlative; single lab\",\n      \"pmids\": [\"16225851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"In mammalian cells, HSPB3 negatively regulates the interaction of HSPB2 with the co-chaperone BAG3: overexpression of HSPB3 reduces HSPB2-BAG3 association, whereas in human myoblasts expressing endogenous HSPB2, HSPB3, HSPB8, and BAG3, BAG3 interacts selectively with HSPB8 and not with HSPB2 or HSPB3.\",\n      \"method\": \"Co-immunoprecipitation in mammalian (overexpression) and human myoblast (endogenous) cells\",\n      \"journal\": \"Cell stress & chaperones\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP in two cellular contexts (overexpression and endogenous), single lab, no in vitro reconstitution\",\n      \"pmids\": [\"28181153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HSPB3 binds to the lamin B receptor (LBR) in the nucleoplasm and maintains LBR in a dynamic state, promoting transcription of myogenic genes including extracellular matrix remodeling genes. Depletion of HSPB3 prevents myoblast differentiation. Overexpression of HSPB3 alone is sufficient to induce differentiation of LHCNM2 and rhabdomyosarcoma cells. The disease-associated mutant R116P-HSPB3 forms nuclear aggregates that immobilize LBR and activates the unfolded protein response, failing to induce differentiation.\",\n      \"method\": \"Co-immunoprecipitation (HSPB3-LBR), FRAP (LBR dynamics), siRNA knockdown, HSPB3 overexpression in human muscle cell lines, immunofluorescence, gene expression analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, FRAP for dynamics, loss-of-function (siRNA) and gain-of-function (overexpression) with defined differentiation phenotype, disease mutant validation; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"33958580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"HSPB3 protein is expressed in motoneurons in vivo (spinal cord of chicken, mouse, and human). Overexpression of wild-type HSPB3 in an avian limb-bud removal model of motoneuron degeneration promotes motoneuron survival, while mutant HSPB3 does not provide the same survival benefit.\",\n      \"method\": \"In ovo overexpression in avian motoneuron degeneration model, immunohistochemistry for endogenous localization, motoneuron survival counts\",\n      \"journal\": \"Experimental neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — defined cellular phenotype (motoneuron survival) with direct localization; single lab, single in vivo assay system\",\n      \"pmids\": [\"27567740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The disease-associated HSPB3 Y118H mutant induces loss of motor activity and reduces mitochondrial membrane potential in Drosophila neuronal tissues. Mitophagy is downregulated in fly motor neurons expressing HSPB3 Y118H. Overexpression of PINK1 and Parkin (core mitophagy regulators) rescues both motor and mitochondrial defects caused by the mutant, placing HSPB3 function upstream of or within the PINK1-Parkin mitophagy pathway in neurons.\",\n      \"method\": \"Drosophila transgenic overexpression, motor activity assays, mitochondrial membrane potential measurement, mitophagy reporter assays, genetic epistasis with PINK1/Parkin\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic epistasis in Drosophila model with defined phenotypic readouts; single lab, first animal model for this mutation\",\n      \"pmids\": [\"37804589\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"HspB3 cDNA encodes a 150-amino-acid polypeptide; among six known human sHSPs it is the most divergent, with a unique N-terminal domain and essentially no C-terminal extension. Northern blot shows expression primarily in smooth muscle tissue.\",\n      \"method\": \"cDNA sequence analysis, Northern blot\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — sequence/expression characterization only, no functional experiment\",\n      \"pmids\": [\"9858786\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HSPB3 is a muscle- and neuron-enriched small heat shock protein that obligately hetero-oligomerizes with HSPB2 in a strict 3:1 (HSPB2:HSPB3) ratio to form a structurally distinct complex (crystal structure resolved) with low intrinsic chaperone activity and no interaction with HSP27, HSP20, or alphaB-crystallin; in the nucleus HSPB3 binds the lamin B receptor (LBR) and keeps it dynamic to drive MyoD-dependent myogenic transcription and differentiation, while in motor neurons it supports survival and mitochondrial quality control via the PINK1-Parkin mitophagy axis, with disease-linked mutations (R116P, Y118H) causing nuclear aggregation, LBR immobilization, mitochondrial dysfunction, and failure of differentiation.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HSPB3 is a muscle- and neuron-enriched small heat shock protein whose defining biochemical feature is obligate hetero-oligomerization with HSPB2 into a muscle-specific complex induced during MyoD-driven myogenic differentiation [#0]. Reconstitution from recombinant proteins establishes that HSPB2 and HSPB3 assemble in a strict 3:1 (HSPB2:HSPB3) ratio into species ranging from tetramers to 24-mers with low surface hydrophobicity and poor chaperone-like activity, and the crystal structure of the full-length hetero-tetramer shows four alpha-crystallin domains forming a flattened tetrahedron held together by IXI/V-motif and N-terminal contacts [#1, #3]. On its own HSPB3 has target-dependent chaperone activity that is constrained by its unusually short C-terminal extension [#2], and incorporation into the HSPB2/B3 complex restricts its interaction repertoire so that it does not associate with HSP20, HSP27, or alphaB-crystallin [#1, #4]; HSPB3 also negatively regulates HSPB2 binding to the co-chaperone BAG3 [#5]. Beyond chaperoning, HSPB3 has a distinct nuclear function: it binds the lamin B receptor (LBR) and keeps it dynamic, and HSPB3 is both required and sufficient to drive myogenic gene transcription and differentiation, with the disease mutant R116P forming nuclear aggregates that immobilize LBR, trigger the unfolded protein response, and block differentiation [#6]. In motor neurons HSPB3 supports neuronal survival [#7], and a disease-associated Y118H mutant causes mitochondrial dysfunction and impaired mitophagy that is rescued by PINK1/Parkin, placing HSPB3 within the PINK1-Parkin mitophagy axis [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that HSPB3 is not a free-standing sHSP but a partner of HSPB2 in a muscle-specific complex that is induced during differentiation, distinguishing it from the canonical sHSP network.\",\n      \"evidence\": \"Co-IP, gel filtration, tissue distribution, and myogenic differentiation assays in myotubes\",\n      \"pmids\": [\"10625651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Subunit stoichiometry of the complex not yet resolved\", \"Functional consequence of the HSPB2/B3 complex unknown\", \"Did not test chaperone activity directly\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined the precise architecture and biochemical character of the complex, showing a fixed 3:1 stoichiometry and explaining its poor chaperone activity via low surface hydrophobicity and a restricted interaction repertoire.\",\n      \"evidence\": \"Native mass spectrometry, analytical ultracentrifugation, CD, ANS hydrophobicity, Co-IP, and in vitro chaperone assays on recombinant proteins\",\n      \"pmids\": [\"19715703\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No physiological substrate identified\", \"Functional role of the complex in cells not addressed\", \"Atomic structure not yet determined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed that HSPB3 alone has intrinsic, target-selective chaperone activity and that its short C-terminal extension is the structural determinant restricting its substrate range.\",\n      \"evidence\": \"Gel filtration, AUC, CD, multi-substrate aggregation assays, and C-terminal chimera engineering with recombinant HspB3\",\n      \"pmids\": [\"22610661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro substrates may not reflect physiological clients\", \"Behavior of free HSPB3 versus complexed HSPB3 in cells unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided an atomic-resolution explanation of how the 3:1 hetero-tetramer assembles, revealing IXI/V-motif and N-terminal contacts and unexpected plasticity in terminal-region interactions.\",\n      \"evidence\": \"X-ray crystallography of the full-length human HspB2/B3 hetero-tetramer\",\n      \"pmids\": [\"29969581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structures of larger oligomeric species not resolved\", \"Structural basis of disease mutations not addressed\", \"Does not explain client recognition\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Placed HSPB3 within the sHSP/co-chaperone regulatory network by showing it modulates HSPB2-BAG3 association, distinguishing its complex from the BAG3-dependent HSPB8 pathway.\",\n      \"evidence\": \"Co-IP in overexpression and endogenous human myoblast contexts\",\n      \"pmids\": [\"28181153\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab, no in vitro reconstitution\", \"Functional consequence of altered HSPB2-BAG3 binding not measured\", \"Mechanism of negative regulation unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Uncovered a chaperone-independent nuclear function: HSPB3 binds LBR and keeps it dynamic to drive myogenic transcription, and demonstrated that a disease mutant immobilizes LBR and blocks differentiation.\",\n      \"evidence\": \"Reciprocal Co-IP, FRAP, siRNA knockdown, overexpression in human muscle cell lines, and disease-mutant validation\",\n      \"pmids\": [\"33958580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking LBR dynamics to transcription not defined\", \"Whether the HSPB2/B3 complex or free HSPB3 mediates this is unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated a neuronal role by showing HSPB3 is expressed in motoneurons and that wild-type, but not mutant, HSPB3 promotes motoneuron survival.\",\n      \"evidence\": \"In ovo overexpression in an avian motoneuron degeneration model with survival counts and immunohistochemistry\",\n      \"pmids\": [\"27567740\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism of survival benefit not defined\", \"Single in vivo assay system\", \"Endogenous loss-of-function not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked the neuronal HSPB3 disease mutant to mitochondrial quality control, showing Y118H impairs mitophagy and is rescued by PINK1/Parkin, placing HSPB3 in the PINK1-Parkin axis.\",\n      \"evidence\": \"Drosophila transgenic models with motor assays, mitochondrial membrane potential, mitophagy reporters, and PINK1/Parkin genetic epistasis\",\n      \"pmids\": [\"37804589\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular target of HSPB3 in the mitophagy pathway unknown\", \"Single lab, first animal model for this mutation\", \"Whether effect is conserved in mammalian motor neurons untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How HSPB3's distinct activities — chaperoning within the HSPB2/B3 complex, nuclear LBR regulation of transcription, and support of mitochondrial quality control in neurons — are mechanistically connected, and how disease mutations disrupt each, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified mechanism linking nuclear and mitochondrial functions\", \"Physiological client proteins of the chaperone activity unidentified\", \"Structural basis of pathogenic mutations not determined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0044183\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 2]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [\"HSPB2/HSPB3 hetero-oligomer\"],\n    \"partners\": [\"HSPB2\", \"LBR\", \"BAG3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":5,"faith_total":5,"faith_pct":100.0}}